Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant SARS-CoV-2 Nucleocapsid antibody

SARS-CoV-2 N Reactivity: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV) ELISA, IF Host: Rabbit Chimeric CR3018 (03-018) unconjugated Recombinant Antibody
Catalog No. ABIN6953059
  • Target See all SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) Antibodies
    SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
    Antibody Type
    Recombinant Antibody
    Reactivity
    • 79
    • 12
    • 5
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV)
    Host
    • 34
    • 25
    • 21
    • 4
    • 1
    • 1
    Rabbit
    Clonality
    • 68
    • 13
    • 4
    Chimeric
    Conjugate
    • 66
    • 11
    • 5
    • 2
    • 1
    This SARS-CoV-2 Nucleocapsid antibody is un-conjugated
    Application
    • 70
    • 35
    • 10
    • 9
    • 6
    • 5
    • 4
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    ELISA, Immunofluorescence (IF)
    Specificity
    This antibody binds the amino acid residues between 11-19 of the N protein of the SARS CoV as well as SARS-CoV-2 (COVID-19) nucleocapsid protein.
    Characteristics

    OriginalSpeciesName: Human

    OriginalFormat: IgG1

    Purification
    Protein A affinity purified
    Immunogen
    The original antibody was generated by cloning the variable regions of the scFvs selected from phage display libraries into separate vectors for IgG1 heavy-chain and light-chain expression. The harvested supernatents were then purified on protein A columns. The original immunogen was the whole irradiated virion.
    Clone
    CR3018 (03-018)
    Isotype
    IgG kappa
    Top Product
    Discover our top product SARS-CoV-2 N Primary Antibody
  • Application Notes
    This antibody is recommended for detection of SARS CoV2 protein N (nucleoprotein). This antibody binds both the nucleocapsid protein of the SARS-CoV and SARS CoV-2 (2019-nCoV). Initial characterization of the antibody for binding to 2019-nCoV was done using ELISA. This antibody shows potential to be used for development of diagnostic assays. Various isotype versions of the antibody namely human IgG1, IgG3, IgM, IgA and the less common IgG2 and IgG4 are available for the investigation of their role in response to SARS CoV2. Competitive ELISA of this antibody with CR3009 suggests that both these antibodies bind different epitopes of the N protein of SARS CoV. Thus, a combination of these two antibodies is suggested for virus capture assays. Immunofluorescence staining was used to demonstrate binding of CR3018 to SARS-CoV infected Vero cells.

    Competitive ELISA of both anti-nucleocapsid antibodies suggests that they bind different, non-overlapping epitopes of the N protein of SARS-CoV. Thus, a combination of these two antibodies is suggested for virus capture assays. Clone CR3018 binds the amino acid residues between 11-19 of the N protein of SARS-CoV, while clone CR3009 binds a non-linear/conformational epitope of the N protein of SARS-CoV, both of which are sufficiently conserved to permit binding of these antibodies to SARS-CoV-2.
    Comment

    This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    PBS with 0.02 % Proclin 300.
    Preservative
    ProClin
    Precaution of Use
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C,-20 °C
    Storage Comment
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Gaynor, Vaysburd, Harman, Albecka, Jeffrey, Beswick, Papa, Chen, Mallery, McGuinness, Van Rietschoten, Stanway, Brear, Lulla, Ciazynska, Chang, Sharp, Neary, Box, Herriott, Kijak, Tatham, Bentley et al.: "Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2. ..." in: Nature communications, Vol. 14, Issue 1, pp. 3583, (2023) (PubMed).

    Ramm, Dondapati, Trinh, Wenzel, Walter, Zemella, Kubick: "The Potential of Eukaryotic Cell-Free Systems as a Rapid Response to Novel Zoonotic Pathogens: Analysis of SARS-CoV-2 Viral Proteins." in: Frontiers in bioengineering and biotechnology, Vol. 10, pp. 896751, (2022) (PubMed).

    van den Brink, Ter Meulen, Cox, Jongeneelen, Thijsse, Throsby, Marissen, Rood, Bakker, Gelderblom, Martina, Osterhaus, Preiser, Doerr, de Kruif, Goudsmit: "Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus." in: Journal of virology, Vol. 79, Issue 3, pp. 1635-44, (2005) (PubMed).

  • Target
    SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
    Alternative Name
    SARS-CoV-2 Nucleocapsid Protein (SARS-CoV-2 N Products)
    Synonyms
    nucleocapsid phosphoprotein antibody, N antibody
    Target Type
    Viral Protein
    Background
    NP, NC, Protein N, Nucleocapsid protein, SARS-CoV Protein N, SARS-CoV Nucleocapsid protein, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV
    UniProt
    P0DTC9, P59595
You are here:
Support